Rifampin resistance and diabetes mellitus in a cross-sectional study of adult patients in rural South India

BMC Infectious Diseases

Research Article

Wesley Bonam¹  John Kenneth²  Syed Fazil Ahamed³  Elaine Ann Yu⁴  Saurabh Mehta⁵ 

[1] Arogyavaram Medical Centre, Andhra Pradesh, India;Arogyavaram Medical Centre, Andhra Pradesh, India;Division of Infectious Diseases, St. John’s Research Institute, Bangalore, Karnataka, India;Division of Infectious Diseases, St. John’s Research Institute, Bangalore, Karnataka, India;Division of Nutritional Sciences, Cornell University, 314 Savage Hall, 14853, Ithaca, NY, USA;Division of Nutritional Sciences, Cornell University, 314 Savage Hall, 14853, Ithaca, NY, USA;Arogyavaram Medical Centre, Andhra Pradesh, India;Division of Infectious Diseases, St. John’s Research Institute, Bangalore, Karnataka, India;

关键词: Tuberculosis;    Drug resistance;    Rifampin;    Diabetes;    India;    Diagnostics;    South Asia;   

DOI  :  10.1186/s12879-015-1204-5

 received in 2015-04-26, accepted in 2015-10-12,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundDespite increasing reports of the linkage between diabetes and tuberculosis (TB), there is limited information regarding diabetes and TB drug resistance.MethodsIn this cross-sectional study, sputum and blood samples were collected from 304 adult patients in rural Andhra Pradesh. Rifampin resistance was assessed by Xpert MTB/RIF (Xpert), and diabetes status was based on self-report. Additionally, samples were assayed by acid-fast bacilli sputum smear microscopy (AFB) and QuantiFERON-TB Gold In-Tube (QFT-G), in order to compare relative diagnostic performances.ResultsAmong patients with confirmed TB (n = 194), diabetes was associated with 3.0-fold higher risk of rifampin resistance (95 % CI 1.3–6.7). Considering Xpert MTB/RIF the gold standard, AFB had lower sensitivity (72.2 vs. 82.5 %) and higher specificity (96.4 vs. 37.0 %) compared to QFT-G for diagnosing TB.ConclusionsThe increased risk of rifampin resistance in patients with diabetes highlights the need for integrated diabetes surveillance in TB programs, particularly in settings undergoing the epidemiological transition.

【 授权许可】

CC BY   
© Mehta et al. 2015